SCHEMBL761853

SCHEMBL761853

C=C(C)C(=O)OCCCCCCCCCC=O

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.65
POLB P06746 1/20 0.49
APEX1 P27695 1/20 0.49
HTT P42858 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
THRB P10828 1/20 0.47
ALDH1A1 P00352 5/20 0.39
CYP3A4 P08684 3/20 0.39
MAPT P10636 3/20 0.36
FAAH O00519 3/20 0.35
TRPV1 Q8NER1 1/20 0.35
USP2 O75604 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34
RECQL P46063 1/20 0.34
NAAA Q02083 1/20 0.33
HPGD P15428 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11523374 1.00 TSHR (0.65) TSHRPOLBAPEX1HTTTDP1
SCHEMBL27552938 1.00 TSHR (0.65) TSHRPOLBAPEX1HTTTDP1
SCHEMBL29218362 1.00 TSHR (0.65) TSHRPOLBAPEX1HTTTDP1
SCHEMBL10925276 0.98 TSHR (0.61) TSHRPOLBAPEX1HTTTDP1
SCHEMBL1949649 0.92 TSHR (0.58) TSHRPOLBAPEX1HTTTDP1
SCHEMBL28038572 0.91 TSHR (0.56) TSHRPOLBAPEX1HTTTDP1
SCHEMBL5836895 0.87 TSHR (0.67) TSHRPOLBAPEX1HTTTDP1
SCHEMBL9170446 0.87 TSHR (0.67) TSHRPOLBAPEX1HTTTDP1
SCHEMBL8699776 0.87 TSHR (0.67) TSHRPOLBAPEX1HTTTDP1
SCHEMBL22554404 0.86 TSHR (0.83) TSHRPOLBAPEX1HTTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592786-B8 DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES USING A FORMYLGLYCINE GENERATING ENZYME (FGE) SHIRE HUMAN GENETIC THERAPIES (US) 2012-03-21 EP disclosed
EP-2217701-A2 GLUCAGON ANTAGONISTS Indiana University Research and Technology Corporation (US) 2010-08-18 EP disclosed
WO-2009058662-A2 GLUCAGON ANTAGONISTS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-05-07 WO disclosed
WO-2009047799-A1 HIGH DOSE SOLID UNIT ORAL PHARMACEUTICAL DOSAGE FORM OF MYCOPHENOLATE SODIUM AND PROCESS FOR MAKING SAME PANACEA BIOTEC LIMITED (IN) 2009-04-16 WO disclosed
WO-2006062608-A2 TUNABLE VEHICLE STRUCTURAL MEMBERS AND METHODS FOR SELECTIVELY CHANGING THE MECHANICAL PROPERTIES THERETO GENERAL MOTORS CORPORATION (US) 2006-06-15 WO disclosed
EP-1592786-A2 DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER USING A FORMYLGLYCINE GENERATING ENZYME (FGE) Transkaryotic Therapies, Inc. (US) 2005-11-09 EP disclosed
WO-2004072275-A2 DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER USING A FORMYLGLYCINE GENERATING ENZYME (FGE) TRANSKARYOTIC THERAPIES, INC. (US) 2004-08-26 WO disclosed
EP-1328261-A2 TREATMENT OF NEURODEGENERATIVE DISEASE Minerva Biotechnologies Corporation (US) 2003-07-23 EP disclosed
WO-2001078709-A2 TREATMENT OF NEURODEGENERATIVE DISEASE MINERVA BIOTECHNOLOGIES CORPORATION (US) 2001-10-25 WO disclosed